Canakinumab

• Description :

  Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

• Stability :

  ≥ 2 years

• Purity :

  >98% (HPLC)

• Molecular Formula :

  ——

• Notes :

  Research use only, not for human use.

• Receptor :

  IL Receptor

• CAS Number :

  914613-48-2